Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
Recruiting
Observational Study
Acute Myeloid Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20 (estimated)
- Sponsor
- University of Freiburg · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
Trial Locations
Sorted by distance from Pennsylvania
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements
* Hematological relapse after allo-HCT
* 18 years or older
Exclusion Criteria:
* no signed informed consent
Contacts